Clinical Trial Update: Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial of nivolumab and ipilimumab in mucinous colorectal and appendiceal tumors was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucinous Adenocarcinoma of the Colon
• Mucinous Adenocarcinoma of the Rectum

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum | Phase 2 | Status: TERMINATED | Results posted: 2022-10-20